MedTrace Logo

Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)

NCT05770882 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2025-03-11

No results posted yet for this study

Summary

This open-label, phase Ib/II, multicenter study evaluated the safety, tolerability, efficacy, and PK of chidamide in combination with regorafenib in patients with HCC. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor. Regorafenib, a receptor tyrosine kinase inhibitor, was approved as second-line systemic treatment for HCC patients.

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

DRUG

Chidamide

Subjects will receive a single dose of chidamide. 5mg tablet. One dose every three days.

DRUG

Regorafenib

Subjects will receive a single dose of Regorafenib. 40mg tablet. One dose daily.

Sponsors & Collaborators

  • Great Novel Therapeutics Biotech & Medicals Corporation

    lead INDUSTRY

Principal Investigators

  • Chia-Nan Chen, Ph.D. · Great Novel Therapeutics Biotech & Medicals Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-25
Primary Completion
2025-01-17
Completion
2025-01-17

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05770882 on ClinicalTrials.gov